Revised Maximum Retail Prices (MRPs) of 1,364 anti-cancer formulations came into effect on Monday, with consumers expected to save an estimated Rs. 3,540.38 crore annually, according to an official release.
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has capped trade margins on the MRP of 137 anti-cancer drugs, based on recommendations submitted by an Expert Committee constituted by the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare, on October 17, 2026.
According to the ministry, 85 pharmaceutical companies had reported revised MRPs for 1,364 anti-cancer formulations covering 121 drugs as of November 8, 2026.
The revised prices are aimed at making essential cancer medicines more affordable and reducing the financial burden on patients.